1. Introduction {#sec1}
===============

Serum uric acid is a strong predictor of stroke \[[@B1]\], coronary artery disease \[[@B2]\], and metabolic syndrome \[[@B3]\]. However, the definite role of uric acid in these diseases is still the subject of much discussion and debate because it is always accompanied with other risk factors such as diet, obesity, and dyslipidemia. Specifically, disputation exists about whether serum uric acid is a causative risk factor or only a coexisting marker of those pathologic processes. The paper published by Framingham Heart Study group argued that the relationship between serum uric acid and cardiovascular disease (CVD) is weak, inconsistent with clinical presentations \[[@B4]\]. The relationship between serum uric acid and dyslipidemia is also complex and not fully elucidated. The objective of our study was to investigate the independent relation between serum uric acid and lipid profiles using by The Third National Health and Nutrition Examination Survey (NHANES III), which represents a well-designed population-based study with a large sample size of US adults.

2. Methods {#sec2}
==========

2.1. Study Population {#sec2.1}
---------------------

Executed during the period between 1988 and 1994, the NHANES III consists of a representative sample of the noninstitutionalized civilian US population, which was selected by using a multistage, stratified sampling, and cluster sampling design \[[@B5]\]. All participants were interviewed for demographic, health, and dietary information. After a detailed home-based interview, participants were invited to receive pertinent examination sessions where blood specimens were collected. For participants who were unable to attend the examination for health reasons, a blood sample was obtained during the home interview. We limited our analysis to participants aged 20 years or older who attended the medical examination and included the 14130 eligible subjects (6752 men and 7378 women) with complete information. The NHANES III study received NCHS Institutional Review Board approval, and informed consent was acquired from participants prior to starting the study.

2.2. Serum Uric Acid and Lipids Measurements {#sec2.2}
--------------------------------------------

The level of serum uric acid was measured by using the Hitachi 737 automated multichannel chemistry analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN, USA). Details concerning data quality control have been published elsewhere \[[@B6]\]. Chemical analyses of total cholesterol, triglycerides, and HDL cholesterol (Hitachi 704 Analyzer) were performed by the Lipoprotein Analytical Laboratory at Johns Hopkins University, Baltimore, Maryland. LDL cholesterol levels were calculated using the Friedewald formula. Both apolipoprotein-B and apolipoprotein AI were measured by radial immunodiffusion (RID) or by Rrate immunonephelometric assay (RIA). All measurements were made with standardized methods having documented accuracy with respect to Centers for Disease Control and Prevention (CDC) reference methods for lipids and lipoproteins.

2.3. Assessment of Covariants {#sec2.3}
-----------------------------

The information of daily intakes of cholesterol, total fat, saturated fatty acids, protein, carbohydrate, and total energy intake was based on Dietary Food Frequency Questionnaire \[[@B7]\]. Reliability and validity of Dietary Food Frequency Questionnaire for dietary had been well assessed previously \[[@B8], [@B9]\]. The participants were interviewed to collect information on age, gender, race, body measurements (including height, weight, and waist), antihyperlipidemic agent, and medical conditions (including self-reported physician-diagnosed diabetes and hypertension). Waist circumference was measured by trained NHANES staff using standard protocols. A brief questionnaire was used to determine the status and amounts of alcoholic beverage. Serum cotinine levels were measured by isotope-dilution high-performance liquid chromatography in tandem with mass spectrometry. Detailed specimen collection and processing instructions are discussed in the NHANES Laboratory Procedures Manual and are available on the NHANES website \[[@B6]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

All statistical analyses were computed using SPSS Complex Samples (Version 18.0 for Windows, SPSS, Inc., Chicago, IL, USA) to incorporate sample weights and adjust for clusters and strata of the complex sample design. We used quintile-based analysis by dividing serum uric acid levels into quintiles with the subjects in the lowest one as the reference group. The cut-off levels for serum uric acid levels quintiles were as follows: *Q*1 ≦ 238 *μ*mol/L, 238 *μ*mol/L \< *Q*2 ≦ 286 *μ*mol/L, 286 *μ*mol/L \< *Q*3 ≦ 327 *μ*mol/L, 327 *μ*mol/L \< *Q*4 ≦ 381 *μ*mol/L, and 381 *μ*mol/L \< *Q*5. We used linear regression modeling to evaluate the relationship between uric acid and lipid levels. We used 3 models with progressive degrees of adjustment. Model 1 was adjusted for age, gender, and race. Model 2 was further adjusted for waist, hypertension, diabetes, drink, cotinine level, and antihyperlipidemic agent use. Model 3 was adjusted for intake of cholesterol, total fat, saturated fatty acids, protein, carbohydrate, and total energy.

3. Results {#sec3}
==========

The population\'s mean age was 44 years. The mean serum uric acid level was 315.84 *μ*mol/L. The characteristics of the study subject quintiles by serum uric acid levels are summarized in [Table 1](#tab1){ref-type="table"}. When serum uric acid levels increased gradually, age; the proportion of men; body mass index; waist; history of hypertension; use of lipid lowering agents; intake of alcohol; cholesterol; total fat; saturated fatty acids; protein; carbohydrate; and total energy tended to increase. Higher serum LDL cholesterol, triglycerides, total cholesterol, apolipoprotein-B levels, and ratio of triglycerides to HDL cholesterol and apolipoprotein-B to AI levels were positively correlated with higher serum uric acid levels, whereas serum HDL cholesterol levels are inversely correlated. After adjusting for age, gender, and race (model 1), serum total cholesterol, triglycerides, LDL cholesterol, and apolipoprotein-B levels in individuals in the highest quintile of serum uric acid levels were higher than in the lowest quintile by 0.46 mmol/L (95% CI 0.41, 0.52; *P* for trend \< 0.001), 0.66 mmol/L (95% CI 0.62, 0.71; *P* for trend \< 0.001), 0.24 mmol/L (95% CI 0.16, 0.32; *P* for trend \< 0.001), and 0.15 g/L (95% CI 0.13, 0.17; *P* for trend \< 0.001), respectively. Serum HDL cholesterol in the highest quintile of serum uric acid levels was lower than in the lowest quintile by 0.16 mmol/L (95% CI 0.14, 0.17; *P* for trend \< 0.001). The correlation remained unchanged after additionally adjusting for other covariates in models 2 and 3 ([Table 2](#tab2){ref-type="table"}). However, serum lipoprotein (a) and serum apolipoprotein AI are weakly associated with serum uric acid levels after additionally adjusting for other covariates in models 2 and 3.

4. Discussion {#sec4}
=============

To the best of our knowledge, there are few studies which focused on the trend of the lipid panels at different levels of uric acid in a nationally representative sample of US adults. Our study illustrated the strong association between serum uric acid and lipid profiles by grading and comprehensively adjusting for confounders. In a survey of 60 patients, Sarmah and Sharma pointed out that serum uric acid levels were associated with the levels of LDL and HDL \[[@B10]\]. A limitation of the previous study was the relatively small sample size, which cannot detect subtle difference of lipid profiles in the clinical setting.

Several important implications can be drawn from our research. First, the level of serum uric acid increased accompanied with increment of serum LDL cholesterol, triglycerides, total cholesterol, and apolipoprotein-B levels. Second, ratios of triglycerides to HDL cholesterol and apolipoprotein-B to AI were also significantly associated with increased uric acid level. Third, there was a strongly inverse relationship between serum uric acid and HDL cholesterol levels regardless of adjustment for sex and several potential confounders, including dietary, hypertension, diabetes, and health related information, suggesting a crucial role of uric acid in the regulation of dyslipidemia. These finding strengthened on previous studies that showed a pathogenesis overlap among hyperuricemia and dyslipidemia \[[@B11], [@B12]\]. When establishing the diagnosis of hyperuricemia, especially at higher levels, clinical suspicion of coexistent dyslipidemia should be required. These abnormalities had a close relationship to coronary artery disease (CAD) and deserved to be taken seriously.

LDL cholesterol, apolipoprotein-B, and ratio of apolipoprotein-B to AI showed linear correlation with serum uric acid even after adjusting covariants. According to earlier published data, apolipoprotein-B represented a better indicator of the truly LDL particle numbers and CAD \[[@B13]\]. In the prospective studies conducted by Walldius and McQueen, the ratio of apolipoprotein-B to AI was also demonstrated to be one of the strongest risk predictors for cardiovascular events \[[@B14], [@B15]\]. These findings strengthen the evidence about the relationship among serum uric acid, dyslipidemia, and CAD risk. It is controversial if serum uric acid is only a marker of preexisting disorder or a causal factor for dyslipidemia and CAD. Increased apolipoprotein-B to AI ratio and insulin levels were evidenced to lower eGFR or decrease renal excretion of uric acid \[[@B16], [@B17]\]. Therefore, these would lead to decreasing uric acid excretion by urine, which cause further hyperuricemia. However, hyperuricemia can affect adipocytes by increasing monocyte chemoattractant protein 1 and reducing production of adiponectin, thereby contributing to insulin resistance and inflammation \[[@B18]--[@B20]\]. In our study, the triglycerides to HDL cholesterol ratio, a reliable indicator of insulin resistance, also showed the positive correlation with serum uric acid. Similarly, previous study revealed in full detail that serum uric acid was associated with increased triglycerides to HDL cholesterol ratio \[[@B21]\]. Decreased insulin resistance in leptin related obesity and fructose-induced metabolic syndrome was noted when lowering uric acid by uricosuric agents and xanthine oxidase inhibitors \[[@B18], [@B22], [@B23]\]. The above-mentioned findings highlighted complex interaction between serum uric acid and lipids.

In our study, serum HDL cholesterol, as a protective factor for CVD risk, is inversely related to uric acid level in line with previous study. It has been lately noted that elevated serum uric acid was a significant predictor of smaller, denser LDL cholesterol and HDL cholesterol particles, which offers a greater atherogenic ability \[[@B24]\]. The decline of HDL cholesterol will give rise to the formation of atherosclerosis and eventually predisposed to cardiovascular disease (CVD), but the direct evidence that increasing HDL cholesterol is beneficial in reducing cardiovascular events has not been established. On the other hand, the connections between triglycerides and uric acid levels were linear and evident \[[@B12], [@B25]\]. This was in complete agreement with our findings. The relationship between triglycerides and uric acid level had been attributed to genetic factors \[[@B26], [@B27]\]. It is tempting to speculate that the synthesis of triglycerides will need NADPH, which resulted in increased uric acid production \[[@B28]\].

It is now widely acceptable to receive antihyperlipidemic drugs to lower the CVD risk. The latest therapeutic strategies for hyperlipidemia attended to risk reduction, instead of the target of exactly lipid level such as LDL cholesterol level for 70 mg/dL \[[@B29]\]. Our study showed strong relationship between uric acid and these lipid profiles. It seems that we cannot just take lipid into account and let uric acid behind. Collectively, our study implied that uric acid might intensify many pathophysiological mechanisms associated with the risk CVD and might have synergistic interactions with other lipid profiles causing CVD. Due to the strong concurrence of dyslipidemia and hyperuricemia, it is urgent to develop appropriate treatment guidelines such as life style modification, diet, and pharmacologic measures taking into account improving hyperuricemia and holistic long-term health effects. Furthermore, in more recent years, prevalence of hyperuricemia was predisposed by the increasing frequency of risk factors, such as obesity and metabolic syndrome \[[@B30]\]. These abnormalities influenced each other by diverse mechanism and precipitated by similar factors such as diet, life style, and genes. Detection and treatment of disordered lipid and uric metabolism in patients with multiple risk factors for CVD should be given a high priority in the clinical setting.

The current analysis had few limitations. This study was performed in a nationally representative sample of US general population; therefore, the findings are likely to be generalizable to the US general population. Although previous reports and biological plausibility consistently suggest that lipid levels would be associated with the serum uric acid levels as observed, a cross-sectional study design tends to leave uncertainty regarding the temporal sequence of exposure, outcome relations. Thus, confirming the relation with prospective longitudinal data (e.g., relation between prior dyslipidemia and incident hyperuricemia) would be valuable. Further investigation of the potentially modifiable impact of apolipoprotein-B or lipoprotein (a) would also be warranted, including clinical trials.

5. Conclusion {#sec5}
=============

From a nationally representative sample of US adults, our study demonstrated that serum LDL cholesterol, triglycerides, total cholesterol, apolipoprotein-B levels, ratio of triglycerides to HDL cholesterol, and ratio of apolipoprotein-B to AI are significantly associated with serum uric acid levels, whereas serum HDL cholesterol levels are inversely associated. The more comprehensive strategic management to deal with dyslipidemia and hyperuricemia deserves further investigation.
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###### 

Characteristics of the study population by serum uric acid quintiles.

                                       Serum uric acid levels (*μ*mol/L)                                                     
  ------------------------------------ ----------------------------------- --------- --------- --------- --------- --------- ---------
  *N*                                  14130                               2749      2764      2674      2843      3100       
  Uric acid (*μ*mol/L)                 315.84                              205.11    265.21    308.72    355.69    442.53    \<0.001
  Age (years)                          44.08                               40.87     43.01     44.41     44.95     47.12     \<0.001
  Sex (% male)                         49.10                               10.40     30.30     53.80     70.50     79.00     \<0.001
  Race (% white)                       84.90                               85.50     84.40     85.60     85.80     83.20     0.21
  Body mass index (Kg/m^2^)            26.63                               24.01     25.45     26.97     27.55     29.11     \<0.001
  Waist (cm)                           92.07                               82.69     88.20     92.95     95.84     100.59    \<0.001
  History of hypertension (%)          23.00                               12.70     20.10     22.80     23.30     36.00     \<0.001
  History of diabetes (%)              5.00                                6.20      4.70      5.00      3.70      6.20      0.49
  Drink/month                          29.00                               15.10     24.50     26.90     34.20     39.30     \<0.001
  Serum cotinine (nmol/L)              451.84                              430.77    458.49    476.21    486.83    407.94    0.79
  Antihyperlipidemic drug use (%)      2.20                                1.40      1.40      1.60      2.60      3.80      \<0.001
  Average daily intakes                                                                                                       
   Calories (kcal/d)                   2223.89                             1909.78   2082.67   2340.35   2410.76   2378.32   \<0.001
   Protein (g/d)                       83.28                               70.46     76.84     87.74     90.32     91.09     \<0.001
   Total carbohydrates (g/d)           271.20                              240.26    259.35    283.73    288.76    284.33    \<0.001
   Total fats (g/d)                    85.37                               74.00     80.09     91.46     92.68     88.89     \<0.001
   Cholesterol (mg/d)                  288.26                              254.80    265.24    301.18    312.09    307.88    \<0.001
   Total saturated fatty acids (g/d)   28.58                               25.22     26.47     31.10     30.88     29.36     \<0.001
  Serum lipids and apolipoproteins                                                                                            
   Total cholesterol (mmol/L)          5.21                                4.93      5.16      5.24      5.33      5.39      \<0.001
   Total cholesterol (% of risk)^\*^   48.4                                38        44.7      49.8      52.7      55.6       
   Triglycerides (mmol/L)              1.49                                1.15      1.35      1.44      1.63      1.84      \<0.001
   Triglycerides (% of risk)^\*^       16.6                                7.9       12        14.5      18.5      27.4       
   HDL cholesterol (mmol/L)            1.25                                1.38      1.32      1.25      1.18      1.13      \<0.001
   HDL cholesterol (% of risk)^\*^     26.3                                13.6      19.8      25.4      31.2      39.4       
   LDL cholesterol (mmol/L)            3.32                                3.08      3.22      3.35      3.46      3.45      \<0.001
   LDL cholesterol (% of risk)^\*^     76.6                                68.5      74.1      78.9      81.6      80.1       
   Apolipoprotein-B (g/L)              1.05                                0.96      1.01      1.05      1.09      1.14      \<0.001
   Apolipoprotein-B (% of risk)^\*^    23.6                                14.1      19.8      22.5      27.1      34.5       
   Lipoprotein (a) (g/L)               0.23                                0.22      0.23      0.24      0.22      0.22      0.424
   Lipoprotein (a) (% of risk)^\*^     32.6                                30.3      32.5      33.2      32        34.7       
   Apolipoprotein AI (g/L)             1.40                                1.46      1.44      1.39      1.36      1.36      \<0.001
   Apolipoprotein AI (% of risk)^\*^   0.6                                 0.7       0.5       0.6       0.4       0.8        

Data are survey-weighted means or percentages for continuous or categorical variables, respectively.

^\*^Risk values of serum lipids and apolipoproteins: total cholesterol \>5.18 mmol/L, triglycerides \>2.26 mmol/L, HDL cholesterol \<1.03 mmol/L, LDL cholesterol \>2.59 mmol/L, serum apolipoprotein-B \>1.25 g/L, serum lipoprotein (a) \>0.3 g/L, and serum apolipoprotein AI \<0.94 g/L.

###### 

Adjusted differences (95% CI) in serum lipids, triglycerides to HDL cholesterol ratio, and apolipoprotein-B to AI ratio comparing the four higher quartiles to the first quartile of serum uric acid.

                                           Serum uric acid levels (*μ*mol/L)                                                                                               
  ---------------------------------------- ----------------------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------
  Total cholesterol (mmol/L)                                                                                                                                                
   Model 1                                 0.00 (Reference)                    0.22 (0.17, 0.27)      0.32 (0.26, 0.37)      0.43 (0.37, 0.49)      0.46 (0.41, 0.52)      \<0.001
   Model 2                                 0.00 (Reference)                    0.18 (0.10, 0.27)      0.19 (0.10, 0.28)      0.24 (0.15, 0.33)      0.30 (0.20, 0.39)      \<0.001
   Model 3                                 0.00 (Reference)                    0.17 (0.09, 0.26)      0.19 (0.10, 0.28)      0.23 (0.14, 0.32)      0.29 (0.19, 0.39)      \<0.001
  Triglycerides (mmol/L)                                                                                                                                                    
   Model 1                                 0.00 (Reference)                    0.18 (0.14, 0.22)      0.28 (0.23, 0.32)      0.46 (0.41, 0.50)      0.66 (0.62, 0.71)      \<0.001
   Model 2                                 0.00 (Reference)                    0.12 (0.06, 0.18)      0.11 (0.05, 0.18)      0.25 (0.19, 0.32)      0.33 (0.26, 0.40)      \<0.001
   Model 3                                 0.00 (Reference)                    0.12 (0.06, 0.18)      0.10 (0.03, 0.17)      0.27 (0.20, 0.33)      0.33 (0.26, 0.41)      \<0.001
  HDL cholesterol (mmol/L)                                                                                                                                                  
   Model 1                                 0.00 (Reference)                    −0.04 (−0.05, −0.02)   −0.08 (−0.09, −0.06)   −0.12 (−0.13, −0.10)   −0.16 (−0.17, −0.14)   \<0.001
   Model 2                                 0.00 (Reference)                    −0.02 (−0.04, 0.00)    −0.05 (−0.08, −0.03)   −0.07 (−0.10, −0.05)   −0.08 (−0.11, −0.05)   \<0.001
   Model 3                                 0.00 (Reference)                    −0.01 (−0.04, 0.01)    −0.05 (−0.07, −0.02)   −0.08 (−0.10, −0.05)   −0.08 (−0.11, −0.05)   \<0.001
  LDL cholesterol (mmol/L)                                                                                                                                                  
   Model 1                                 0.00 (Reference)                    0.10 (0.03, 0.18)      0.19 (0.12, 0.27)      0.28 (0.21, 0.36)      0.24 (0.16, 0.32)      \<0.001
   Model 2                                 0.00 (Reference)                    0.08 (−0.04, 0.19)     0.13 (0.01, 0.25)      0.21 (0.09, 0.33)      0.14 (0.01, 0.27)      0.015
   Model 3                                 0.00 (Reference)                    0.08 (−0.03, 0.20)     0.13 (0.01, 0.24)      0.20 (0.08, 0.33)      0.14 (0.01, 0.27)      0.022
  Apolipoprotein-B (g/L)                                                                                                                                                    
   Model 1                                 0.00 (Reference)                    0.05 (0.03, 0.07)      0.08 (0.06, 0.10)      0.12 (0.10, 0.14)      0.15 (0.13, 0.17)      \<0.001
   Model 2                                 0.00 (Reference)                    0.04 (0.01, 0.07)      0.03 (0.00, 0.06)      0.06 (0.03, 0.09)      0.08 (0.05, 0.12)      \<0.001
   Model 3                                 0.00 (Reference)                    0.04 (0.02, 0.07)      0.03 (0.00, 0.06)      0.06 (0.03, 0.09)      0.09 (0.05, 0.12)      \<0.001
  Lipoprotein (a) (g/L)                                                                                                                                                     
   Model 1                                 0.00 (Reference)                    0.01 (−0.12, 0.03)     0.02 (0.00, 0.04)      0.01 (−0.01, 0.03)     0.00 (−0.02, 0.02)     0.962
   Model 2                                 0.00 (Reference)                    0.01 (−0.02, 0.04)     0.02 (−0.02, 0.05)     0.02 (−0.01, 0.05)     0.02 (−0.02, 0.05)     0.373
   Model 3                                 0.00 (Reference)                    0.01 (−0.03, 0.04)     0.01 (−0.03, 0.04)     0.01 (−0.02, 0.05)     0.00 (−0.03, 0.04)     0.559
  Apolipoprotein AI (g/L)                                                                                                                                                   
   Model 1                                 0.00 (Reference)                    −0.01 (−0.02, 0.01)    −0.03 (−0.05, −0.01)   −0.04 (−0.06, −0.02)   −0.04 (−0.06, −0.02)   \<0.001
   Model 2                                 0.00 (Reference)                    0.03 (0.01, 0.05)      −0.03 (−0.05, 0.00)    −0.01 (−0.03, 0.02)    0.02 (−0.01, 0.05)     0.740
   Model 3                                 0.00 (Reference)                    0.03 (0.00, 0.05)      −0.02 (−0.05, 0.00)    −0.01 (−0.04, 0.02)    0.01 (−0.02, 0.04)     0.738
  Triglycerides to HDL cholesterol ratio                                                                                                                                    
   Model 1                                 0.00 (Reference)                    0.16 (0.11, 0.21)      0.27 (0.21, 0.32)      0.48 (0.42, 0.53)      0.72 (0.67, 0.78)      \<0.001
   Model 2                                 0.00 (Reference)                    0.09 (0.01, 0.17)      0.10 (0.02, 0.18)      0.27 (0.19, 0.36)      0.33 (0.25, 0.42)      \<0.001
   Model 3                                 0.00 (Reference)                    0.08 (0.00, 0.17)      0.08 (0.00, 0.17)      0.29 (0.20, 0.37)      0.35 (0.0.26, 0.44)    \<0.001
  Apolipoprotein-B to AI ratio                                                                                                                                              
   Model 1                                 0.00 (Reference)                    0.04 (0.02, 0.05)      0.07 (0.06, 0.09)      0.11 (0.09, 0.12)      0.14 (0.12, 0.15)      \<0.001
   Model 2                                 0.00 (Reference)                    0.02 (0.00, 0.04)      0.04 (0.01, 0.06)      0.05 (0.02, 0.08)      0.06 (0.03, 0.09)      \<0.001
   Model 3                                 0.00 (Reference)                    0.02 (0.00, 0.05)      0.03 (0.01, 0.06)      0.05 (0.03.0.08)       0.06 (0.03, 0.09)      \<0.001

Adjusted covariates: model 1 = age, gender, and race; model 2 = model 1 + waist, hypertension, diabetes, alcohol drink, cotinine level, and antihyperlipidemic drug use; model 3 = model 2 + intake of total energy (kcal/day), protein (g/day), carbohydrates (g/day), total fats (g/day), cholesterol (mg/day), and total saturated fatty acids (g/day).
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